Literature DB >> 21945603

The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism.

Vincenzo Marzolla1, Andrea Armani, Maria-Christina Zennaro, Francesca Cinti, Caterina Mammi, Andrea Fabbri, Giuseppe M C Rosano, Massimiliano Caprio.   

Abstract

Aldosterone controls blood pressure by binding to the mineralocorticoid receptor (MR), a ligand-activated transcription factor which regulates critical genes controlling salt and water homeostasis in the kidney. In recent years, inappropriate MR activation has been shown to trigger deleterious responses in various tissues, including vessels, heart and brain, hence promoting vascular inflammation, cardiovascular remodeling, endothelial dysfunction, and oxidative stress. Moreover, epidemiological studies have shown a clear association between aldosterone levels and the incidence of metabolic syndrome. In particular, recent work has revealed functional MRs in adipose tissue, where they mediate the effects of aldosterone and glucocorticoids, displaying important and specific functions involving adipose differentiation, expansion and proinflammatory capacity. This recent evidence finally moved MR out of the shadow of the glucocorticoid receptor (GR), which had previously been considered the only player mediating corticosteroid action in adipose tissue. This has opened a new era of research focusing on the complexity and selectivity of MR function in adipocyte biology. The aim of this review is to summarize the latest concepts on the role of MR in white and brown adipocytes, and to discuss the potential benefits of tissue-selective MR blockade in the treatment of obesity and metabolic syndrome.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21945603     DOI: 10.1016/j.mce.2011.09.011

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  38 in total

Review 1.  Cortisol dysregulation in obesity-related metabolic disorders.

Authors:  Rene Baudrand; Anand Vaidya
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-06       Impact factor: 3.243

2.  New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects.

Authors:  Ana Paula Davel; Iris Z Jaffe; Rita C Tostes; Frederic Jaisser; Eric J Belin de Chantemèle
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-29       Impact factor: 4.733

3.  Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults.

Authors:  Jennifer N Cooper; Linda Fried; Ping Tepper; Emma Barinas-Mitchell; Molly B Conroy; Rhobert W Evans; Maria Mori Brooks; Genevieve A Woodard; Kim Sutton-Tyrrell
Journal:  Hypertens Res       Date:  2013-05-09       Impact factor: 3.872

Review 4.  Nuclear receptors in neural stem/progenitor cell homeostasis.

Authors:  Dimitrios Gkikas; Matina Tsampoula; Panagiotis K Politis
Journal:  Cell Mol Life Sci       Date:  2017-06-21       Impact factor: 9.261

Review 5.  The Role of Aldosterone in Obesity-Related Hypertension.

Authors:  Wakako Kawarazaki; Toshiro Fujita
Journal:  Am J Hypertens       Date:  2016-02-28       Impact factor: 2.689

Review 6.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

Review 7.  Mineralocorticoid receptors in the pathogenesis of insulin resistance and related disorders: from basic studies to clinical disease.

Authors:  Guanghong Jia; Warren Lockette; James R Sowers
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-01-13       Impact factor: 3.619

8.  Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension.

Authors:  Tanja Dudenbostel; Lama Ghazi; Mingchun Liu; Peng Li; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2016-08-15       Impact factor: 10.190

9.  Aldosterone deficiency prevents high-fat-feeding-induced hyperglycaemia and adipocyte dysfunction in mice.

Authors:  P Luo; A Dematteo; Z Wang; L Zhu; A Wang; H-S Kim; A Pozzi; J M Stafford; J M Luther
Journal:  Diabetologia       Date:  2013-01-12       Impact factor: 10.122

10.  Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats.

Authors:  G Youcef; A Olivier; N Nicot; A Muller; C Deng; C Labat; R Fay; R-M Rodriguez-Guéant; C Leroy; F Jaisser; F Zannad; P Lacolley; L Vallar; A Pizard
Journal:  Br J Pharmacol       Date:  2016-04-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.